DK1827461T3 - CLADRIBIN REGULATION FOR TREATMENT OF MULTIPLE SCLEROSIS - Google Patents

CLADRIBIN REGULATION FOR TREATMENT OF MULTIPLE SCLEROSIS

Info

Publication number
DK1827461T3
DK1827461T3 DK05823474.1T DK05823474T DK1827461T3 DK 1827461 T3 DK1827461 T3 DK 1827461T3 DK 05823474 T DK05823474 T DK 05823474T DK 1827461 T3 DK1827461 T3 DK 1827461T3
Authority
DK
Denmark
Prior art keywords
multiple sclerosis
treatment
cladribin
regulation
preparation
Prior art date
Application number
DK05823474.1T
Other languages
Danish (da)
Inventor
Luca Giampiero De
Arnaud Ythier
Alain Munafo
Maria Lopez-Bresnahan
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Priority claimed from PCT/EP2005/056954 external-priority patent/WO2006067141A1/en
Application granted granted Critical
Publication of DK1827461T3 publication Critical patent/DK1827461T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)

Abstract

The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.
DK05823474.1T 2004-12-22 2005-12-20 CLADRIBIN REGULATION FOR TREATMENT OF MULTIPLE SCLEROSIS DK1827461T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
PCT/EP2005/056954 WO2006067141A1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
DK1827461T3 true DK1827461T3 (en) 2012-03-26

Family

ID=34930135

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05823474.1T DK1827461T3 (en) 2004-12-22 2005-12-20 CLADRIBIN REGULATION FOR TREATMENT OF MULTIPLE SCLEROSIS

Country Status (10)

Country Link
AT (1) ATE547106T1 (en)
DK (1) DK1827461T3 (en)
ES (4) ES2428741T3 (en)
HU (1) HUE035859T2 (en)
LT (1) LT2805723T (en)
ME (1) ME01333B (en)
PT (3) PT2805723T (en)
RS (1) RS52219B (en)
SI (1) SI1827461T1 (en)
UA (1) UA96260C2 (en)

Also Published As

Publication number Publication date
HUE035859T2 (en) 2018-05-28
RS52219B (en) 2012-10-31
LT2805723T (en) 2018-02-12
ATE547106T1 (en) 2012-03-15
PT2805723T (en) 2018-01-25
ES2382554T3 (en) 2012-06-11
ES2666146T3 (en) 2018-05-03
SI1827461T1 (en) 2012-05-31
ES2495392T3 (en) 2014-09-17
ME01333B (en) 2013-12-20
UA96260C2 (en) 2011-10-25
PT1827461E (en) 2012-05-07
ES2428741T3 (en) 2013-11-11
PT3332789T (en) 2022-07-05

Similar Documents

Publication Publication Date Title
EA201001669A1 (en) SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
TW200806300A (en) New therapeutic combinations for the treatment of depression
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
SG170069A1 (en) Quinoline derivatives
GEP20156348B (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
SG160391A1 (en) Cladribine regimen for treating multiple sclerosis
TW200833670A (en) Novel compounds 569
TW200745122A (en) New compounds I
MX2014008446A (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines.
BRPI0407181A (en) Pharmaceutical Formulation
DE60219005D1 (en) SOLID PHARMACEUTICAL FORMULATION CONTAINING MODAFINIL
MA29278B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN INDOLYLMALEIMIDE DERIVATIVE
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
SE0303480D0 (en) Benzofuranes
WO2007111983A3 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
BRPI0618370A2 (en) aerosol drug formulation, drug use and inhalation kit
TW200635592A (en) Pyridyl-substituted spiro-hydantoin compounds and use thereof
WO2007099323A3 (en) Quinoline derivatives
HK1107699A1 (en) Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound
DK1827461T3 (en) CLADRIBIN REGULATION FOR TREATMENT OF MULTIPLE SCLEROSIS
WO2006048336A3 (en) Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents